oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes align more closely with attained dose than achieved weight loss semaglutide cardiovascular trial New Science

Additional Information How to cite this article : Song, X

This cohort of patients has a high risk for atrial fibrillation (AF) and was seen in diabetic and obese atrial fibrillation patients

These results come primarily from SURMOUNT-1, a large phase 3 trial of 2,539 adults with obesity or overweight and at least one weight-related complication, who did not have diabetes

"Talking it through with your physician can help you make a safer, more informed decision." Its important to consult your doctor first With all substances, if you don't have all the information about what could or couldn't happen when you take a medication, you might be caught off guard by a reaction or side effects," Dr

However, this is uncommon with standard Neurobion Injection use